Mimedx Group, Inc. (MDXG)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1376339 · fiscal year ends in Dec
Closing price $3.97 on 29 Oct 2026; 52-week range $3.08 to $7.96.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $303.7M
- Revenue growth
- -22.8%
- Net income, last twelve months
- -$19.2M
- Earnings per share
- -$0.13
- Gross margin
- 77.3%
- Operating margin
- -8.3%
- Net margin
- -6.3%
- Free cash flow
- $19.1M
- Return on equity
- -9.1%
- Market value
- $579.3M
- Cash
- $120.8M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 145.9M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2025 | 31 Dec 2025 | $418.6M | $63.9M | $48.6M | $0.32 | $73.0M | 10-K filed 25 Feb 2026 |
| FY2024 | 31 Dec 2024 | $348.9M | $58.9M | $42.4M | $0.28 | $64.5M | 10-K filed 26 Feb 2025 |
| FY2023 | 31 Dec 2023 | $321.5M | $37.1M | $58.2M | $0.37 | $24.8M | 10-K filed 28 Feb 2024 |
| FY2022 | 31 Dec 2022 | $267.8M | -$14.7M | -$30.2M | -$0.33 | -$19.4M | 10-K filed 28 Feb 2023 |
| FY2021 | 31 Dec 2021 | $242.0M | -$7.1M | -$10.3M | -$0.15 | -$5.2M | 10-K filed 28 Feb 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q3 FY2026 | 30 Sep 2026 | $62.3M | -$8.7M | -$0.06 |
| Q2 FY2026 | 30 Jun 2026 | $64.4M | -$14.8M | -$0.10 |
| Q1 FY2026 | 31 Mar 2026 | $59.0M | -$10.9M | -$0.07 |
| Q4 FY2025 | 31 Dec 2025 | $118.1M | $15.2M | $0.10 |
| Q3 FY2025 | 30 Sep 2025 | $113.7M | $16.7M | $0.11 |
| Q2 FY2025 | 30 Jun 2025 | $98.6M | $9.6M | $0.06 |
| Q1 FY2025 | 31 Mar 2025 | $88.2M | $7.0M | $0.05 |
| Q4 FY2024 | 31 Dec 2024 | $92.9M | $7.4M | $0.05 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By product, FY2025
| Segment | Revenue | Share |
|---|---|---|
| Wound | $276.3M | 66.0% |
| Surgical | $142.3M | 34.0% |
Company events
The newest 8-K filings of 280 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 28 Oct 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 16 Oct 2026 | 8-K | Other events | 8.01 |
| 11 Aug 2026 | 8-K/A | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 29 Jul 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 29 Jul 2026 | 8-K | Material agreement, Investor update | 1.01, 7.01, 9.01 |
| 16 Jun 2026 | 8-K | Shareholder vote, Bylaws or fiscal year change | 5.03, 5.07 |
| 29 Apr 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 16 Apr 2026 | 8-K | Leadership change, Investor update | 5.02, 7.01, 9.01 |
| 25 Feb 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 12 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 29 Oct 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 3 Sep 2025 | 8-K | Investor update | 7.01 |
Every filing
The newest filings with the SEC of 608 held.
| Filed | Form | Period |
|---|---|---|
| 28 Oct 2026 | 425 | – |
| 28 Oct 2026 | 8-K | 28 Oct 2026 |
| 28 Oct 2026 | 10-Q | 30 Sep 2026 |
| 16 Oct 2026 | 425 | – |
| 16 Oct 2026 | 8-K | 15 Oct 2026 |
| 4 Sep 2026 | EFFECT | – |
| 25 Aug 2026 | S-4 | – |
| 11 Aug 2026 | 425 | – |
| 11 Aug 2026 | 8-K/A | 29 Jul 2026 |
| 30 Jul 2026 | 425 | – |
| 30 Jul 2026 | 425 | – |
| 29 Jul 2026 | 425 | – |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 6 Nov 2025 | Maersk-Moller Kimberly, Chief Commercial Officer | Sale outside a trading plan | 58,300 | $7.42 | $432.3K | 236,982 | 10 Nov 2025 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 6 Nov 2025 | Kimberly Ann Maersk-Moller, Officer | 68,587 | $502.7K | 6 Nov 2025 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 13 Feb 2026 | Trigran Investments, Inc. | 13G amended | 4.2% | 6.2M |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 9.3M | -1.05% | 9.08 |
| 30 Sep 2026 | 9.4M | -12.99% | 7.35 |
| 15 Sep 2026 | 10.8M | +14.66% | 10.87 |
| 31 Aug 2026 | 9.4M | +5.55% | 9.48 |
| 14 Aug 2026 | 8.9M | +5.41% | 6.87 |
| 31 Jul 2026 | 8.4M | +12.14% | 5.32 |
| 15 Jul 2026 | 7.5M | -0.08% | 7.15 |
| 30 Jun 2026 | 7.5M | -2.34% | 4.67 |
Funds that hold it
From each fund's latest Form 13F.
277 funds held it at 30 Jun 2026: 126 added and 60 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| Essex Woodlands Management, Inc. | 28,195,249 | $108.6M | 0 |
| BlackRock, Inc. | 12,154,466 | $46.8M | +243,166 |
| Nantahala Capital Management, LLC | 9,535,104 | $36.7M | – |
| Trigran Investments, Inc. | 7,173,770 | $27.6M | -1,339 |
| State Street Corp. | 5,578,920 | $21.5M | +522,119 |
| Vanguard Capital Management LLC | 5,187,053 | $20.0M | +21,047 |
| Paradigm Capital Management Inc. | 4,073,100 | $15.7M | +662,800 |
| Geode Capital Management, LLC | 3,143,488 | $12.1M | +262,329 |
| Goldman Sachs Group Inc. | 2,665,562 | $10.3M | +1,480,001 |
| AQR Capital Management LLC | 2,467,005 | $9.5M | +1,554,277 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B